Our Vision

Glycobia is committed to rapidly commercializing new and affordable biotherapeutic drugs synthesized from the bottom-up.

Our Technology

Glycobia employs proprietary BUG™ (bottom-up glycoengineering) technology to design bacteria that produce novel and enhanced biotherapeutics to address unmet medical needs.

Recent News

August 20, 2012

Entrepreneur turns bacterial daydream into successful start-up Read C&EN Article

February 9, 2012

Glycobia is Cornell University's inaugural resident of the Kevin M. McGovern Family Center for Venture Development in the Life Sciences.